

# Persontilpasset KI-basert nevrodiagnostikk




Esten H. Leonardsen

Post-doktor ved Psykologisk Institutt,  
Universitetet i Oslo


Vitenskapelig ansvarlig, baba.vision



UNIVERSITETET  
I OSLO




# KI-revolusjonen(?)



McKinsey & Company, The state of AI: How organizations are rewiring to capture value,  
<https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai> (2025)




# KI-revolusjonen(?)



<https://pubmed.ncbi.nlm.nih.gov/>, publikasjoner som inneholder "(neurology OR neuroscience OR neuroimaging) AND (ai OR artificial intelligence OR deep learning)"




# KI-revolusjonen(?)



Leonardsen, E. H., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*, 7(1), 110

# KI-revolusjonen(?)




# KI-revolusjonen(?)

"Innføringen av KI i helse- og omsorgstjenesten har gått saktere enn noen forventet i starten av planperioden"


Helsedirektoratet (2023). Status og forslag til videre arbeid med kunstig intelligens (KI) i helse- og omsorgstjenesten. Oslo: Helsedirektoratet (siste faglige endring 26. oktober 2023). Tilgjengelig fra <https://www.helsedirektoratet.no/rapporter/status-og-forslag-til-videre-arbeid-med-kunstig-intelligens-ki-i-helse-og-omsorgstjenesten>



# Utfordringer: Forklarbarhet




# Utfordringer: Forklarbarhet




# Utfordringer: Forklarbarhet

Kunstig intelligens




# Utfordringer: Forklarbarhet


Kunstig intelligens



Menneskelige forskere



# Utfordringer: Nytteverdi



baba.vision



baba.vision





**Esten Leonardsen**  
Chief Scientific Officer



**Per Wessel Nore**  
Chief Executive Officer



**Guro Seternes**  
Chief Technology Officer



**Lars T. Westlye**  
Professor, UiO



**Yunpeng Wang**  
Professor, UiO




**Thomas Wolfers**  
Professor, UT



**Anders Eikenes**  
CEO, Oivi

<https://mlflow-server-531474577141.us-central1.run.app/#/experiments/0>






# Prediksjon av behandlingsrespons



**European Medicines Agency reviews  
and revises its opinion on Lecanemab**




# Prediksjon av behandlingsrespons



Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*.




# Prediksjon av behandlingsrespons




Villain, N., Planche, V., & Levy, R. (2022). High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.  
*Revue neurologique.*

# Prediksjon av behandlingsrespons




# Prediksjon av behandlingsrespons




# Prediksjon av behandlingsrespons

## Mulighetsstudie



Takk for oppmerksomheten!  
[estenhl@uios.no](mailto:estenhl@uios.no)



UNIVERSITETET  
I OSLO